Related Experiment Videos
Sentinel node biopsy in breast cancer.
G Zavagno1, R Busolin, F Bozza
1Istituto di Clinica Chirurgica II, Università di Padova, Padova, Italy.
Breast (Edinburgh, Scotland)
|January 21, 2004
Summary
Sentinel node (SN) biopsy is a reliable method for staging breast cancer axilla, correctly predicting status in most cases. Further standardization and trials are needed before SN biopsy can replace axillary lymph node dissection (ALND).
Area of Science:
- Oncology
- Surgical Pathology
- Radiopharmaceuticals
Background:
- Axillary lymph node dissection (ALND) is crucial for breast cancer staging but carries risks and complications.
- Increasing early diagnoses lead to more negative ALND results, prompting investigation into less invasive staging methods.
- Sentinel node (SN) biopsy offers a potentially less invasive alternative to ALND for axillary staging.
Purpose of the Study:
- To evaluate the reliability of sentinel node (SN) biopsy as an indicator for axillary staging in breast cancer patients.
- To compare the accuracy of SN biopsy with the status of other axillary lymph nodes.
Main Methods:
- 126 patients with T1-T2 breast cancer and clinically negative axilla were studied.
- 99mTC-labelled colloidal albumin was injected near the tumor, and SNs were visualized using lymphoscintigraphy.
- SNs were surgically removed using a gamma ray-detecting probe, followed by ALND and histopathologic examination.
Main Results:
- SNs were identified and biopsied in 91.3% (115/126) of patients.
- SN biopsy correctly predicted axillary status in 95.6% (110/115) of cases.
- False-negative results occurred in 4.4% (5/115) of cases, with positive nodes found in the remaining axilla.
Conclusions:
- SN biopsy demonstrates good reliability for axillary staging in breast cancer.
- Further standardization of technical aspects is necessary for widespread clinical adoption.
- Clinical trials are required to clarify the prognostic implications of false-negative SN biopsy results.